Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL1907605 Target Snapshot

Cyclin-dependent kinase 2/cyclin E1 · PROTEIN COMPLEX · Homo sapiens

3,602Compounds
337Assays
5Approved Drugs
4,248.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Protein identity stays anchored to UniProt P24864. Use UniProt P24864 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt P24864 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Cyclin-dependent kinase 2/cyclin E1 as ChEMBL target CHEMBL1907605, mapped to UniProt P24864. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Cyclin-dependent kinase 2/cyclin E1
PROTEIN COMPLEX · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL1907605
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P24864
G1/S-specific cyclin-E1
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Cyclin-dependent kinase 2/cyclin E1 is the right protein anchor across sources, using UniProt P24864 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelG1/S-specific cyclin-E1
UniProt AccessionP24864
Component TypeProtein
Sequence Length410 aa

G1/S-specific cyclin-E1

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Cyclin-dependent kinase 2/cyclin E1, mapped to UniProt P24864. ChEMBL maps the protein component as G1/S-specific cyclin-E1. Sequence length is 410 aa.

Mapped IDP24864
Review nameCyclin-dependent kinase 2/cyclin E1
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

5
Approved
3
Phase III
20
Phase II
10
Phase I
Assay Mix

Activity Type Distribution

IC502,727.0
KI1,501.0
EC5020.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5899718 10.4 Ki 0.04 Preclinical
CHEMBL5762472 10.3 Ki 0.05 Preclinical
CHEMBL5774115 10.22 Ki 0.06 Preclinical
CHEMBL5817327 10.22 Ki 0.06 Preclinical
CHEMBL5857215 10.22 Ki 0.06 Preclinical
CHEMBL5808436 10.15 Ki 0.07 Preclinical
CHEMBL5975537 10.15 Ki 0.07 Preclinical
CHEMBL5278622 10.1 Ki 0.08 Preclinical
CHEMBL5764489 10.1 Ki 0.08 Preclinical
CHEMBL5805501 10.1 Ki 0.08 Preclinical
Distribution

pChEMBL Value Distribution

128
5.0
146
5.5
214
6.0
348
6.5
196
7.0
150
7.5
290
8.0
505
8.5
393
9.0
260
9.5
pChEMBL
Approved Drugs

Approved Drugs

ABEMACICLIB
CHEMBL3301610
Approved 2017
Assay Landscape

Assay Landscape

337
Total Assays
2,204
Tested Compounds
2
Assay Types
Binding — 336 assays, 2,204 compounds
BAO Format Assays Compounds Avg pChEMBL
protein complex format 214 757 6.4
cell-based format 91 511 6.7
assay format 31 936 8.8
ADME — 1 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
protein complex format 1 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine